Immunoprecise Antibodies Ltd
XTSX:IPA
Immunoprecise Antibodies Ltd
Research & Development
Immunoprecise Antibodies Ltd
Research & Development Peer Comparison
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Immunoprecise Antibodies Ltd
XTSX:IPA
|
Research & Development
-CA$2m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Research & Development
-$175.7m
|
CAGR 3-Years
-81%
|
CAGR 5-Years
-98%
|
CAGR 10-Years
N/A
|
|
Arch Biopartners Inc
XTSX:ARCH
|
Research & Development
-CA$5.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-64%
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Research & Development
-CA$514.3k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
1%
|
CAGR 10-Years
7%
|
|
Innovotech Inc
XTSX:IOT
|
Research & Development
-CA$186k
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
11%
|
See Also
What is Immunoprecise Antibodies Ltd's Research & Development?
Research & Development
-2m
CAD
Based on the financial report for Apr 30, 2021, Immunoprecise Antibodies Ltd's Research & Development amounts to -2m CAD.
What is Immunoprecise Antibodies Ltd's Research & Development growth rate?
Research & Development CAGR 3Y
-57%
Over the last year, the Research & Development growth was -338%. The average annual Research & Development growth rates for Immunoprecise Antibodies Ltd have been -57% over the past three years .